Shenzhen Financial Statements From 2010 to 2025
| SHEZF Stock | USD 0.47 0.00 0.00% |
Check Shenzhen Hepalink financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Shenzhen Hepalink's main balance sheet or income statement drivers, such as , as well as many indicators such as . Shenzhen financial statements analysis is a perfect complement when working with Shenzhen Hepalink Valuation or Volatility modules.
Shenzhen |
Shenzhen Hepalink Pharmaceutical Company Return On Equity Analysis
Shenzhen Hepalink's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Shenzhen Hepalink Return On Equity | 0.0351 |
Most of Shenzhen Hepalink's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Shenzhen Hepalink Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Shenzhen Hepalink Pharmaceutical has a Return On Equity of 0.0351. This is 100.15% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The return on equity for all United States stocks is 111.32% lower than that of the firm.
Shenzhen Hepalink Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Shenzhen Hepalink's current stock value. Our valuation model uses many indicators to compare Shenzhen Hepalink value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Shenzhen Hepalink competition to find correlations between indicators driving Shenzhen Hepalink's intrinsic value. More Info.Shenzhen Hepalink Pharmaceutical is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers reporting about 0.80 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Shenzhen Hepalink Pharmaceutical is roughly 1.24 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Shenzhen Hepalink's earnings, one of the primary drivers of an investment's value.About Shenzhen Hepalink Financial Statements
Shenzhen Hepalink stakeholders use historical fundamental indicators, such as Shenzhen Hepalink's revenue or net income, to determine how well the company is positioned to perform in the future. Although Shenzhen Hepalink investors may analyze each financial statement separately, they are all interrelated. For example, changes in Shenzhen Hepalink's assets and liabilities are reflected in the revenues and expenses on Shenzhen Hepalink's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Shenzhen Hepalink Pharmaceutical. Please read more on our technical analysis and fundamental analysis pages.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the Peoples Republic of China. Shenzhen Hepalink operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 2046 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Shenzhen Pink Sheet
Shenzhen Hepalink financial ratios help investors to determine whether Shenzhen Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shenzhen with respect to the benefits of owning Shenzhen Hepalink security.